Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

FGFR1 inhibitor

DRUG CLASS:

FGFR1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	cetuximab + BMS-582664 Resistant: A2 - Guideline cetuximab + BMS-582664 Resistant : A2	cetuximab + BMS-582664 Resistant: A2 - Guideline cetuximab + BMS-582664 Resistant : A2
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	HMPL-453 Sensitive: C2 – Inclusion Criteria HMPL-453 Sensitive : C2	HMPL-453 Sensitive: C2 – Inclusion Criteria HMPL-453 Sensitive : C2
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 expression	Neuroendocrine Tumor	PD-L1 expression	Neuroendocrine Tumor	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
FGFR2-ARHGAP24 fusion	Cholangiocarcinoma	FGFR2-ARHGAP24 fusion	Cholangiocarcinoma	TT-00434 Sensitive: C3 – Early Trials TT-00434 Sensitive : C3	TT-00434 Sensitive: C3 – Early Trials TT-00434 Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D